NASDAQ:CURNeuralstem Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Neuralstem, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $0.76 -0.03 (-3.78 %) (As of 07/14/2020 04:00 PM ET) Add Compare Share Today's Range$0.75Now: $0.76▼$0.7950-Day Range$0.72MA: $0.84▼$0.9652-Week Range$1.10Now: $0.76▼$13.78Volume465,000 shsAverage Volume1.98 million shsMarket Capitalization$1.60 millionP/E RatioN/ADividend YieldN/ABeta1.81 ProfileAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Neuralstem, Inc., a clinical stage biopharmaceutical company, focuses on the research and development of nervous system therapies based on its proprietary human neuronal stem cells and small molecule compounds. The company's stem cell based technology enables the isolation and expansion of human neural stem cells from various areas of the developing human brain and spinal cord enabling the generation of physiologically relevant human neurons of various types. Its lead product candidate is NSI-189, a chemical entity, which has been completed Phase II clinical trial for the treatment of major depressive disorder, as well as is in preclinical study for the treatment-refractory depression, Angelman Syndrome, Alzheimer's disease, ischemic stroke, diabetic neuropathy, irradiation-induced cognitive deficit, and long-term potentiation enhancement. The company also develops NSI-566, which has completed Phase II clinical trial for treating amyotrophic lateral sclerosis disease; Phase II clinical trial for the treatment of chronic ischemic stroke; and Phase I clinical trials for the treatment of chronic spinal cord injury, as well as is in preclinical study for the traumatic brain injury. In addition, it develops NSI-532, which is in preclinical study for treatment of Alzheimer's disease; and NSI-777 that is in preclinical study for treatment of human demyelinating diseases. Neuralstem, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Neuralstem. Previous Next 2.5 Community Rank Outperform VotesNeuralstem has received 278 “outperform” votes. (Add your “outperform” vote.)Underperform VotesNeuralstem has received 276 “underperform” votes. (Add your “underperform” vote.)Community SentimentNeuralstem has received 50.18% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Neuralstem and other stocks. Vote “Outperform” if you believe CUR will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CUR will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldNeuralstem does not currently pay a dividend.Dividend GrowthNeuralstem does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Neuralstem insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.38% of the stock of Neuralstem is held by insiders.Percentage Held by Institutions38.30% of the stock of Neuralstem is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Price to Book Value per Share RatioNeuralstem has a P/B Ratio of 0.11. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 0.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.83 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CUR Previous Symbol CUSIPN/A CIK1357459 Webwww.neuralstem.com Phone301-366-4841Debt Debt-to-Equity RatioN/A Current Ratio2.53 Quick Ratio2.53Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$260,000.00 Price / Sales6.17 Cash FlowN/A Price / Cash FlowN/A Book Value$6.64 per share Price / Book0.11Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-4,930,000.00 Net Margins-39,417.64% Return on Equity-170.51% Return on Assets-110.16%Miscellaneous Employees6 Outstanding Shares2,100,000Market Cap$1.60 million Next Earnings DateN/A OptionableOptionable NASDAQ:CUR Rates by TradingView Receive CUR News and Ratings via Email Sign-up to receive the latest news and ratings for CUR and its competitors with MarketBeat's FREE daily newsletter. Neuralstem (NASDAQ:CUR) Frequently Asked Questions How has Neuralstem's stock been impacted by COVID-19 (Coronavirus)? Neuralstem's stock was trading at $0.7516 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, CUR stock has increased by 1.6% and is now trading at $0.7634. View which stocks have been most impacted by Coronavirus. How were Neuralstem's earnings last quarter? Neuralstem, Inc. (NASDAQ:CUR) announced its earnings results on Wednesday, August, 14th. The company reported ($1.45) earnings per share for the quarter. The firm earned $0.01 million during the quarter. Neuralstem had a negative return on equity of 170.51% and a negative net margin of 39,417.64%. View Neuralstem's earnings history. When did Neuralstem's stock split? How did Neuralstem's stock split work? Shares of Neuralstem reverse split on Thursday, July 18th 2019. The 1-20 reverse split was announced on Tuesday, July 16th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, July 17th 2019. An investor that had 100 shares of Neuralstem stock prior to the reverse split would have 5 shares after the split. Has Neuralstem been receiving favorable news coverage? Press coverage about CUR stock has trended somewhat negative recently, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Neuralstem earned a coverage optimism score of -1.5 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View the latest news about Neuralstem. Who are some of Neuralstem's key competitors? Some companies that are related to Neuralstem include Gene Biotherapeutics (CRXM), CytRx (CYTR), Innate Pharma (IPHA), Mymetics (MYMX) and Omni Bio Pharmaceutical (OMBP). View all competitors. What other stocks do shareholders of Neuralstem own? Based on aggregate information from My MarketBeat watchlists, some companies that other Neuralstem investors own include XOMA (XOMA), MannKind (MNKD), Cytokinetics (CYTK), Turkcell Iletisim Hizmetleri A.S. (TKC), Idera Pharmaceuticals (IDRA), NovaBay Pharmaceuticals (NBY), ACADIA Pharmaceuticals (ACAD), Athersys (ATHX), Caladrius Biosciences (CLBS) and Rexahn Pharmaceuticals (REXN). Who are Neuralstem's key executives? Neuralstem's management team includes the following people: Dr. Kenneth C. Carter, Exec. Chairman, CEO & Principal Financial Officer (Age 59)Dr. Karl Y. Johe, Co-Founder (Age 59)Dr. Thomas G. Hazel Ph.D., Sr. VP of ResearchDr. David P. Recker, Chief Medical Officer (Age 61) What is Neuralstem's stock symbol? Neuralstem trades on the NASDAQ under the ticker symbol "CUR." How do I buy shares of Neuralstem? Shares of CUR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Neuralstem's stock price today? One share of CUR stock can currently be purchased for approximately $0.76. How big of a company is Neuralstem? Neuralstem has a market capitalization of $1.60 million and generates $260,000.00 in revenue each year. Neuralstem employs 6 workers across the globe. What is Neuralstem's official website? The official website for Neuralstem is www.neuralstem.com. How can I contact Neuralstem? Neuralstem's mailing address is 20271 Goldenrod Lane, Germantown MD, 20876. The company can be reached via phone at 301-366-4841 or via email at [email protected] This page was last updated on 7/14/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
